Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Rheumatoid Arthritis

Free Subscription Articles published in Ann Rheum Dis Retrieve available abstracts of 230 articles: HTML format

Single Articles

March 2023
1. YAMADA S, Nagafuchi Y, Wang M, Ota M, et al
   Immunomics analysis of rheumatoid arthritis identified precursor dendritic cells as a key cell subset of treatment resistance.
   Ann Rheum Dis. 2023 Mar 14:ard-2022-223645. doi: 10.1136/ard-2022-223645.
   PubMed     Abstract available
   
   
   
2. HUSS V, Bower H, Hellgren K, Frisell T, et al
   Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-world cohort study.
   Ann Rheum Dis. 2023 Mar 3:ard-2022-223636. doi: 10.1136/ard-2022-223636.
   PubMed     Abstract available
   
   
   
3. 
   Correction: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
   Ann Rheum Dis. 2023;82:e76.
   PubMed    
   
   
   
4. 
   News from EULAR.
   Ann Rheum Dis. 2023;82:448.
   PubMed    
   
   
   
5. LOPES AP, Hillen MR, Hinrichs AC, Blokland SL, et al
   Deciphering the role of cDC2s in Sjogren's syndrome: transcriptomic profile links altered antigen processes with IFN signature and autoimmunity.
   Ann Rheum Dis. 2023;82:374-383.
   PubMed     Abstract available
   
   
   
6. WANG B, Chen S, Xuan J, Li Y, et al
   Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial'.
   Ann Rheum Dis. 2023;82:e67.
   PubMed    
   
   
   
7. FELTEN R, Gottenberg JE
   Response to: 'Correspondence on 'Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial'' by Wang et al.
   Ann Rheum Dis. 2023;82:e68.
   PubMed    
   
   
   
8. AYDIN SZ, Hepworth E, Tugwell P
   Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
   Ann Rheum Dis. 2023;82:e69.
   PubMed    
   
   
   
9. FREITES NUNEZ DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, et al
   Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Aydin et al.
   Ann Rheum Dis. 2023;82:e70.
   PubMed    
   
   
   
10. MOUTSOPOULOS HM
    Correspondence on 'Jan Gosta Waldenstrom and rheumatology'.
    Ann Rheum Dis. 2023;82:e59.
    PubMed    
    
    
    
11. NOVELLA-NAVARRO M, Plasencia-Rodriguez C, Tornero C, Navarro-Compan V, et al
    Correspondence on: 'EULAR definition of difficult-to-treat rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e55.
    PubMed    
    
    
    
12. ROODENRIJS NMT, Welsing PMJ, van der Goes MC, Jacobs JW, et al
    Response to: 'Correspondence on 'EULAR definition of difficult-to-treat rheumatoid arthritis'' by Novella-Navarro et al.
    Ann Rheum Dis. 2023;82:e56.
    PubMed    
    
    
    February 2023
13. SMITH SL, Alexander S, Nair N, Viatte S, et al
    Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis.
    Ann Rheum Dis. 2023 Feb 21:annrheumdis-2022-222519. doi: 10.1136/ard-2022-222519
    PubMed     Abstract available
    
    
    
14. FRISELL T, Bower H, Morin M, Baecklund E, et al
    Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme.
    Ann Rheum Dis. 2023 Feb 14:ard-2022-223762. doi: 10.1136/ard-2022-223762.
    PubMed     Abstract available
    
    
    
15. O'NEIL LJ, Oliveira CB, Wang X, Navarrete M, et al
    Neutrophil extracellular trap-associated carbamylation and histones trigger osteoclast formation in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Feb 3:ard-2022-223568. doi: 10.1136/ard-2022-223568.
    PubMed     Abstract available
    
    
    
16. 
    Correction: Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis.
    Ann Rheum Dis. 2023;82:e53.
    PubMed    
    
    
    
17. TARANNUM S, Widdifield J, Wu CF, Johnson SR, et al
    Understanding sex-related differences in healthcare utilisation among patients with inflammatory arthritis: a population-based study.
    Ann Rheum Dis. 2023;82:283-291.
    PubMed     Abstract available
    
    
    
18. POMBO-SUAREZ M, Sanchez-Piedra C, Gomez-Reino J, Lauper K, et al
    After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
    Ann Rheum Dis. 2023;82:175-181.
    PubMed     Abstract available
    
    
    
19. HOSONO Y, Sie B, Pinal-Fernandez I, Pak K, et al
    Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1gamma autoantibodies.
    Ann Rheum Dis. 2023;82:246-252.
    PubMed     Abstract available
    
    
    
20. SUN T, Ni J
    Correspondence on 'Prevotella copri in individuals at risk for rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e50.
    PubMed    
    
    
    
21. GILBERT BTP, Finckh A, Alpizar Rodriguez D
    Response to: 'Correspondence on 'Prevotella copri in individuals at risk for rheumatoid arthritis'' by Sun and Ni.
    Ann Rheum Dis. 2023;82:e51.
    PubMed    
    
    
    
22. DE COCK D, Soenen I, Bertrand D, Pazmino S, et al
    Correspondence on 'EULAR recommendations for a core data set for pregnancy registries in rheumatology'.
    Ann Rheum Dis. 2023;82:e44.
    PubMed    
    
    
    
23. RUYSSEN-WITRAND A, Soubrier M, Basch A, Truchetet ME, et al
    Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort'.
    Ann Rheum Dis. 2023;82:e32.
    PubMed    
    
    
    
24. CIUREA A, Finckh A
    Response to 'Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort' by Ruyssen-Witrand et al.
    Ann Rheum Dis. 2023;82:e33.
    PubMed    
    
    
    January 2023
25. DOUGADOS M, Charles-Schoeman C, Szekanecz Z, Giles JT, et al
    Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
    Ann Rheum Dis. 2023 Jan 31:ard-2022-223406. doi: 10.1136/ard-2022-223406.
    PubMed    
    
    
    
26. NII T, Maeda Y, Motooka D, Naito M, et al
    Genomic repertoires linked with pathogenic potency of arthritogenic Prevotella copri isolated from the gut of patients with rheumatoid arthritis.
    Ann Rheum Dis. 2023 Jan 10:annrheumdis-2022-222881. doi: 10.1136/ard-2022-222881
    PubMed     Abstract available
    
    
    
27. KERSCHBAUMER A, Stimakovits NM, Smolen JS, Stefanova T, et al
    Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis.
    Ann Rheum Dis. 2023 Jan 10:ard-2022-223349. doi: 10.1136/ard-2022-223349.
    PubMed     Abstract available
    
    
    
28. POPE JE, Fleischmann RM
    Jack pot! What can we learn about registries with respect to treatment cycling in rheumatoid arthritis?
    Ann Rheum Dis. 2023 Jan 6:ard-2022-223071. doi: 10.1136/ard-2022-223071.
    PubMed    
    
    
    
29. GWINNUTT JM, Wieczorek M, Balanescu A, Bischoff-Ferrari HA, et al
    2021 EULAR recommendations regarding lifestyle behaviours and work participation to prevent progression of rheumatic and musculoskeletal diseases.
    Ann Rheum Dis. 2023;82:48-56.
    PubMed     Abstract available
    
    
    
30. VAN MULLIGEN E, de Jong PHP
    Response to: 'Correspondence on 'Tapering towards DMARD-free remission in rheumatoid arthritis' by Garcia et al.
    Ann Rheum Dis. 2023;82:e10.
    PubMed    
    
    
    
31. GARCIA IE, Abud-Mendoza C
    Correspondence on 'Tapering towards DMARD-free remission in rheumatoid arthritis'.
    Ann Rheum Dis. 2023;82:e9.
    PubMed    
    
    
    
32. JONG GP, Pan LF, Lin TK, Chen HY, et al
    Correspondence on 'Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease'.
    Ann Rheum Dis. 2023;82:e11.
    PubMed    
    
    
    
33. LOGSTRUP BB, Olesen KKW, Masic D, Gyldenkerne C, et al
    Response to 'Correspondence on 'Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease" by Jong et al.
    Ann Rheum Dis. 2023;82:e12.
    PubMed    
    
    
    
34. SCHULZE-KOOPS H, Skapenko A, Krause A, Krueger K, et al
    Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.
    Ann Rheum Dis. 2023;82:e1.
    PubMed    
    
    
    
35. FREITES NUNEZ DD, Leon L, Mucientes A, Rodriguez-Rodriguez L, et al
    Response to: 'Correspondence on 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'' by Schulze-Koops et al.
    Ann Rheum Dis. 2023;82:e2.
    PubMed    
    
    
    December 2022
36. HEBING RC, Lin M, Bulatovic Calasan M, Muller IB, et al
    Pharmacokinetics of oral and subcutaneous methotrexate in red and white blood cells in patients with early rheumatoid arthritis: the methotrexate monitoring trial.
    Ann Rheum Dis. 2022 Dec 21:ard-2022-223398. doi: 10.1136/ard-2022-223398.
    PubMed     Abstract available
    
    
    
37. VAN OUWERKERK L, Boers M, Emery P, de Jong PH, et al
    Individual patient data meta-analysis on continued use of glucocorticoids after their initiation as bridging therapy in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Dec 16:ard-2022-223443. doi: 10.1136/ard-2022-223443.
    PubMed     Abstract available
    
    
    
38. KRONZER VL, Sparks JA
    Occupational inhalants, genetics and the respiratory mucosal paradigm for ACPA-positive rheumatoid arthritis.
    Ann Rheum Dis. 2022 Dec 6:ard-2022-223286. doi: 10.1136/ard-2022-223286.
    PubMed    
    
    
    
39. TANG B, Liu Q, Ilar A, Wiebert P, et al
    Occupational inhalable agents constitute major risk factors for rheumatoid arthritis, particularly in the context of genetic predisposition and smoking.
    Ann Rheum Dis. 2022 Dec 6:ard-2022-223134. doi: 10.1136/ard-2022-223134.
    PubMed     Abstract available
    
    
    
40. CURTIS JR, Yamaoka K, Chen YH, Bhatt DL, et al
    Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
    Ann Rheum Dis. 2022 Dec 5:annrheumdis-2022-222543. doi: 10.1136/ard-2022-222543.
    PubMed     Abstract available
    
    
    
41. CALISKAN Y
    News from EULAR.
    Ann Rheum Dis. 2022;81:1767.
    PubMed    
    
    
    
42. KAWANO Y, Patel NJ, Wang X, Cook CE, et al
    Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave.
    Ann Rheum Dis. 2022;81:1742-1749.
    PubMed     Abstract available
    
    
    
43. PRINGLE S, Verstappen GM, Bootsma H, Kroese FGM, et al
    Role of interaction between B cells and epithelial cells in pSS.
    Ann Rheum Dis. 2022;81:e260.
    PubMed    
    
    
    
44. RIVIERE E, Mariette X, Nocturne G
    Response to: 'Role of interaction between B cells and epithelial cells in pSS' by Pringle et al.
    Ann Rheum Dis. 2022;81:e261.
    PubMed    
    
    
    
45. WU BY, Chan CH, Wei JC
    Correspondence to 'Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases'.
    Ann Rheum Dis. 2022;81:e243.
    PubMed    
    
    
    
46. HE P, Zhu H, Wu LF, Deng FY, et al
    Response to 'Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'' by Wang and Niu.
    Ann Rheum Dis. 2022;81:e259.
    PubMed    
    
    
    
47. WANG H, Niu L
    Correspondence on 'Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells'.
    Ann Rheum Dis. 2022;81:e258.
    PubMed    
    
    
    November 2022
48. SOLOMON DH, Giles JT, Liao KP, Ridker PM, et al
    Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Nov 30:ard-2022-223302. doi: 10.1136/ard-2022-223302.
    PubMed     Abstract available
    
    
    
49. BERGSTRA SA, Sepriano A, Kerschbaumer A, van der Heijde D, et al
    Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Ann Rheum Dis. 2022 Nov 21:ard-2022-223358. doi: 10.1136/ard-2022-223358.
    PubMed     Abstract available
    
    
    
50. SEPRIANO A, Kerschbaumer A, Bergstra SA, Smolen JS, et al
    Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Ann Rheum Dis. 2022 Nov 14. pii: ard-2022-223357. doi: 10.1136/ard-2022-223357.
    PubMed     Abstract available
    
    
    
51. KERSCHBAUMER A, Sepriano A, Bergstra SA, Smolen JS, et al
    Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Ann Rheum Dis. 2022 Nov 11. pii: ard-2022-223365. doi: 10.1136/ard-2022-223365.
    PubMed     Abstract available
    
    
    
52. SMOLEN JS, Landewe RBM, Bergstra SA, Kerschbaumer A, et al
    EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.
    Ann Rheum Dis. 2022 Nov 10. pii: ard-2022-223356. doi: 10.1136/ard-2022-223356.
    PubMed     Abstract available
    
    
    
53. PAPPAS DA, St John G, Etzel CJ, Fiore S, et al
    Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US
    Ann Rheum Dis. 2022;81:e225.
    PubMed    
    
    
    
54. ZHENG W, Leong PY, Wei JC
    Correspondence to 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry stu
    Ann Rheum Dis. 2022;81:e224.
    PubMed    
    
    
    
55. KEDOR C, Zernicke J, Feist E
    Response to: 'Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'' by Muraviov and Muraviova.
    Ann Rheum Dis. 2022;81:e234.
    PubMed    
    
    
    
56. RUSCITTI P, Stamm TA, Giacomelli R
    Response to: 'Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'' by Muraviov and Muraviova.
    Ann Rheum Dis. 2022;81:e233.
    PubMed    
    
    
    
57. MURAVIOV Y, Muraviova L
    Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'.
    Ann Rheum Dis. 2022;81:e232.
    PubMed    
    
    
    
58. RUSCITTI P, Bruno F, Berardicurti O, Acanfora C, et al
    Response to: 'Correspondence on 'Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences' by Ruscitti et al' by Ch
    Ann Rheum Dis. 2022;81:e221.
    PubMed    
    
    
    October 2022
59. STUDENIC P, Aletaha D, de Wit M, Stamm TA, et al
    American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision.
    Ann Rheum Dis. 2022 Oct 24. pii: ard-2022-223413. doi: 10.1136/ard-2022-223413.
    PubMed     Abstract available
    
    
    
60. ZHENG Z, Chang L, Mu J, Ni Q, et al
    Database of synovial T cell repertoire of rheumatoid arthritis patients identifies cross-reactive potential against pathogens including unencountered SARS-CoV-2.
    Ann Rheum Dis. 2022 Oct 19. pii: ard-2022-222763. doi: 10.1136/ard-2022-222763.
    PubMed    
    
    
    
61. GESSL I, Hana CA, Deimel T, Durechova M, et al
    Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis.
    Ann Rheum Dis. 2022 Oct 19. pii: ard-2022-222787. doi: 10.1136/ard-2022-222787.
    PubMed     Abstract available
    
    
    
62. TU J, Chen W, Fang Y, Han D, et al
    PU.1 promotes development of rheumatoid arthritis via repressing FLT3 in macrophages and fibroblast-like synoviocytes.
    Ann Rheum Dis. 2022 Oct 5. pii: ard-2022-222708. doi: 10.1136/ard-2022-222708.
    PubMed     Abstract available
    
    
    
63. HOISNARD L, Pina Vegas L, Dray-Spira R, Weill A, et al
    Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study.
    Ann Rheum Dis. 2022 Oct 5. pii: ard-2022-222824. doi: 10.1136/ard-2022-222824.
    PubMed     Abstract available
    
    
    
64. DOUMEN M, Pazmino S, Bertrand D, De Cock D, et al
    Longitudinal trajectories of fatigue in early RA: the role of inflammation, perceived disease impact and early treatment response.
    Ann Rheum Dis. 2022;81:1385-1391.
    PubMed     Abstract available
    
    
    
65. YANG Y, He X, Yao M, Xing W, et al
    Response to: 'Correspondence to: 'Combination of human umbilical cord mesenchymal stem cell transplantation with IFN-gamma treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'' by Ma et al.
    Ann Rheum Dis. 2022;81:e207.
    PubMed    
    
    
    
66. MA KS, Wang LT, Tsai SY
    Correspondence to: 'Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-gamma treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'.
    Ann Rheum Dis. 2022;81:e206.
    PubMed    
    
    
    
67. VAN MULLIGEN E, de Jong PHP
    Response to: 'Tapering antirheumatic drugs in a resource-poor setting: real-world evidence' by Haroon et al.
    Ann Rheum Dis. 2022;81:e209.
    PubMed    
    
    
    
68. HAROON M, Khan Z, Aamer M
    Tapering antirheumatic drugs in a resource-poor setting: real-world evidence.
    Ann Rheum Dis. 2022;81:e208.
    PubMed    
    
    
    
69. ANSARIN K, Taghizadieh A, Safiri S, Malek Mahdavi A, et al
    COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs.
    Ann Rheum Dis. 2022;81:e190.
    PubMed    
    
    
    September 2022
70. MOLANDER V, Bower H, Frisell T, Delcoigne B, et al
    Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 Sep 23. pii: ard-2022-223050. doi: 10.1136/ard-2022-223050.
    PubMed     Abstract available
    
    
    
71. CHARLES-SCHOEMAN C, Buch MH, Dougados M, Bhatt DL, et al
    Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance
    Ann Rheum Dis. 2022 Sep 22. pii: ard-2022-222259. doi: 10.1136/ard-2022-222259.
    PubMed     Abstract available
    
    
    
72. FEIST E, Fatenejad S, Grishin S, Korneva E, et al
    Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled
    Ann Rheum Dis. 2022 Sep 15. pii: ard-2022-222630. doi: 10.1136/ard-2022-222630.
    PubMed     Abstract available
    
    
    August 2022
73. CHENG M, Zhao Y, Cui Y, Zhong C, et al
    Stage-specific roles of microbial dysbiosis and metabolic disorders in rheumatoid arthritis.
    Ann Rheum Dis. 2022 Aug 19. pii: ard-2022-222871. doi: 10.1136/ard-2022-222871.
    PubMed     Abstract available
    
    
    
74. BALANESCU AR, Citera G, Pascual-Ramos V, Bhatt DL, et al
    Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
    Ann Rheum Dis. 2022 Aug 3. pii: ard-2022-222405. doi: 10.1136/ard-2022-222405.
    PubMed     Abstract available
    
    
    
75. HUGLE T
    Learning from chess engines: how reinforcement learning could redefine clinical decision-making in rheumatology.
    Ann Rheum Dis. 2022;81:1072-1075.
    PubMed    
    
    
    
76. CARDENAS-DE LA GARZA JA, Arvizu-Rivera RI, Galarza-Delgado DA
    Should patients starting biologics be screened for COVID-19?
    Ann Rheum Dis. 2022;81:e150.
    PubMed    
    
    
    July 2022
77. SMEELE HTW, Roder E, Mulders AGMGJ, Steegers EAP, et al
    Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients' offspring.
    Ann Rheum Dis. 2022 Jul 11. pii: ard-2022-222679. doi: 10.1136/ard-2022-222679.
    PubMed     Abstract available
    
    
    
78. SEROR R, Baron G, Camus M, Cornec D, et al
    Development and preliminary validation of the Sjogren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjogren's syndrome.
    Ann Rheum Dis. 2022;81:979-989.
    PubMed     Abstract available
    
    
    
79. BAI W, Liu H, Dou L, Yang Y, et al
    Pilot study of baricitinib for active Sjogren's syndrome.
    Ann Rheum Dis. 2022;81:1050-1052.
    PubMed    
    
    
    
80. VAN DER MEULEN TA, Vissink A, Bootsma H, Spijkervet FKL, et al
    Microbiome in Sjogren's syndrome: here we are.
    Ann Rheum Dis. 2022;81:e114.
    PubMed    
    
    
    
81. MANASSON J, Blank RB, Scher JU
    Response to: 'Microbiome in Sjogren's syndrome: here we are' by van der Meulen et al.
    Ann Rheum Dis. 2022;81:e115.
    PubMed    
    
    
    June 2022
82. QIN Y, Cai ML, Jin HZ, Huang W, et al
    Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-alpha-mediated ERK1/2 and JAK-STAT1 pathways.
    Ann Rheum Dis. 2022 Jun 27. pii: ard-2022-222605. doi: 10.1136/ard-2022-222605.
    PubMed     Abstract available
    
    
    
83. KERSCHBAUMER A, Rivai ZI, Smolen JS, Aletaha D, et al
    Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis.
    Ann Rheum Dis. 2022 Jun 20. pii: annrheumdis-2021-221807.
    PubMed     Abstract available
    
    
    
84. NEMETH T, Nagy G, Pap T
    Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go?
    Ann Rheum Dis. 2022 Jun 17. pii: annrheumdis-2021-222021.
    PubMed     Abstract available
    
    
    
85. LAUPER K, Ludici M, Mongin D, Bergstra SA, et al
    Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
    Ann Rheum Dis. 2022 Jun 15. pii: annrheumdis-2022-222586.
    PubMed     Abstract available
    
    
    
86. VISMAN IM, Boers M, Vedder D, Twisk JW, et al
    Routine treatment of rheumatoid arthritis with biologics and targeted agents: changes in patients and their response over 15 years.
    Ann Rheum Dis. 2022 Jun 14. pii: annrheumdis-2022-222207.
    PubMed    
    
    
    
87. COOLES FAH, Tarn J, Lendrem DW, Naamane N, et al
    Interferon-alpha-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming.
    Ann Rheum Dis. 2022 Jun 9. pii: annrheumdis-2022-222370.
    PubMed     Abstract available
    
    
    
88. KVIEN TK
    EULAR 75-year anniversary: commentaries on key ARD papers from 1947.
    Ann Rheum Dis. 2022;81:751-752.
    PubMed    
    
    
    
89. DELCOIGNE B, Ljung L, Provan SA, Glintborg B, et al
    Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries.
    Ann Rheum Dis. 2022;81:789-797.
    PubMed     Abstract available
    
    
    
90. DROSOS GC, Vedder D, Houben E, Boekel L, et al
    EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.
    Ann Rheum Dis. 2022;81:768-779.
    PubMed     Abstract available
    
    
    
91. RUSCITTI P, Stamm TA, Giacomelli R
    Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease.
    Ann Rheum Dis. 2022;81:e103.
    PubMed    
    
    
    
92. KEDOR C, Listing J, Zernicke J, Feist E, et al
    Response to: 'Changing the outcome measures, changing the results? The urgent need of a specific Disease Activity Score to adult-onset Still's disease' by Ruscitti et al.
    Ann Rheum Dis. 2022;81:e104.
    PubMed    
    
    
    
93. MINOIA F, Ravelli A
    Response to: 'Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease associated macrophage activation syndrome' by Zhang et al.
    Ann Rheum Dis. 2022;81:e100.
    PubMed    
    
    
    
94. ZHANG L, Yang X, Li TF, Liu X, et al
    Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease-associated macrophage activation syndrome.
    Ann Rheum Dis. 2022;81:e99.
    PubMed    
    
    
    May 2022
95. BOERS M, Hartman L, Opris-Belinski D, Bos R, et al
    Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.
    Ann Rheum Dis. 2022 May 31. pii: annrheumdis-2021-221957.
    PubMed     Abstract available
    
    
    
96. DAIEN C, Krogulec M, Gineste P, Steens JM, et al
    Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFalpha therapy: a placebo-controlled phase II study.
    Ann Rheum Dis. 2022 May 31. pii: annrheumdis-2022-222228.
    PubMed     Abstract available
    
    
    
97. BUGATTI S, De Stefano L, D'Onofrio B, Nicrosini A, et al
    Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis.
    Ann Rheum Dis. 2022 May 27. pii: annrheumdis-2022-222436.
    PubMed     Abstract available
    
    
    
98. ROUDIER J
    Correspondence on "Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis" by Maggi et al.
    Ann Rheum Dis. 2022 May 20. pii: annrheumdis-2022-222750.
    PubMed    
    
    
    
99. ROSENBAUM JT, Gill T, Martin TM, Friedman M, et al
    Marking the 50th anniversary of a seminal paper in rheumatology: did Baruj Benacerraf and Hugh McDevitt get it right?
    Ann Rheum Dis. 2022;81:618-621.
    PubMed    
    
    
    
100. BROEREN MGA, Wang JJ, Balzaretti G, Groenen PJTA, et al
     Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjogren's syndrome.
     Ann Rheum Dis. 2022;81:644-652.
     PubMed     Abstract available
     
     
     
101. BUCH MH, Maksymowych WP, Boers M
     Managing the selection of placebo group switched to experimental treatment group in post-randomised controlled trial extension studies.
     Ann Rheum Dis. 2022;81:741-742.
     PubMed    
     
     
     April 2022
102. DE STEFANO L, D'Onofrio B, Sakellariou G, Manzo A, et al
     Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic.
     Ann Rheum Dis. 2022 Apr 29. pii: annrheumdis-2022-222264.
     PubMed    
     
     
     
103. VAN OUWERKERK L, Palmowski A, Nevins IS, Buttgereit F, et al
     Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis.
     Ann Rheum Dis. 2022 Apr 25. pii: annrheumdis-2022-222338.
     PubMed     Abstract available
     
     
     
104. SAEVARSDOTTIR S, Stefansdottir L, Sulem P, Thorleifsson G, et al
     Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset.
     Ann Rheum Dis. 2022 Apr 25. pii: annrheumdis-2021-221754.
     PubMed     Abstract available
     
     
     
105. REIJM S, Brehler AS, Rantapaa-Dahlqvist S, Kawakami A, et al
     Cross-reactivity of anti-modified protein antibodies is also present in predisease and individuals without rheumatoid arthritis.
     Ann Rheum Dis. 2022 Apr 22. pii: annrheumdis-2022-222326.
     PubMed    
     
     
     
106. MAGGI J, Carrascal M, Soto L, Neira O, et al
     Isolation of HLA-DR-naturally presented peptides identifies T-cell epitopes for rheumatoid arthritis.
     Ann Rheum Dis. 2022 Apr 22. pii: annrheumdis-2021-220371.
     PubMed     Abstract available
     
     
     
107. VAN LINT JA, van Hunsel FPAM, Tas SW, Vonkeman HE, et al
     Hypoglycaemia following JAK inhibitor treatment in patients with diabetes.
     Ann Rheum Dis. 2022;81:597-599.
     PubMed    
     
     
     
108. SAPER VE, Chen G, Guillerman RP, Khatri P, et al
     Response to: 'Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease' by Sato et al.
     Ann Rheum Dis. 2022;81:e62.
     PubMed    
     
     
     
109. STUDENIC P, Felson DT, de Wit M, Smolen JS, et al
     Response to: 'Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis' by Bugatti et al.
     Ann Rheum Dis. 2022;81:e56.
     PubMed    
     
     
     March 2022
110. VERSTAPPEN M, Huizinga TW, van der Helm-van Mil AH
     No excess mortality in contemporary undifferentiated arthritis, in contrast to rheumatoid arthritis: a study with a follow-up of at least 10 years.
     Ann Rheum Dis. 2022 Mar 2. pii: annrheumdis-2022-222145.
     PubMed    
     
     
     
111. BOWER H, Frisell T, Di Giuseppe D, Delcoigne B, et al
     Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?
     Ann Rheum Dis. 2022;81:433-439.
     PubMed     Abstract available
     
     
     
112. LIU D, Zhang F, Cao H, Wang X, et al
     Can sexual dimorphism in rheumatoid arthritis be attributed to the different abundance of Gardnerella?
     Ann Rheum Dis. 2022;81:e36.
     PubMed    
     
     
     
113. YAMAMOTO M, Yoshikawa N, Tanaka H
     Efficacy of dupilumab reveals therapeutic target for IgG4-related disease: simultaneous control of inflammation and fibrosis.
     Ann Rheum Dis. 2022;81:e50.
     PubMed    
     
     
     
114. REGUEIRO C, Gonzalez A
     Questions on 'Sequencing of the MHC region defines HLA-DQA1 as the major genetic risk for seropositive rheumatoid arthritis in Han Chinese population' by Guo et al.
     Ann Rheum Dis. 2022;81:e38.
     PubMed    
     
     
     
115. MARTINSSON K, Durholz K, Schett G, Zaiss MM, et al
     Higher serum levels of short-chain fatty acids are associated with non-progression to arthritis in individuals at increased risk of RA.
     Ann Rheum Dis. 2022;81:445-447.
     PubMed    
     
     
     
116. SAPER VE, Ombrello MJ, Tremoulet AH, Montero-Martin G, et al
     Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles.
     Ann Rheum Dis. 2022;81:406-415.
     PubMed     Abstract available
     
     
     
117. GHALANDARI N, Kemper E, Crijns IH, Wolbink G, et al
     Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy.
     Ann Rheum Dis. 2022;81:402-405.
     PubMed     Abstract available
     
     
     February 2022
118. ARAUJO CSR, Medeiros-Ribeiro AC, Saad CGS, Bonfiglioli KR, et al
     Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
     Ann Rheum Dis. 2022 Feb 22. pii: annrheumdis-2021-221916.
     PubMed     Abstract available
     
     
     
119. LOPEZ-ROMERO P, de la Torre I, Haladyj E, Aletaha D, et al
     Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis.
     Ann Rheum Dis. 2022 Feb 22. pii: annrheumdis-2021-221323.
     PubMed     Abstract available
     
     
     
120. FELSON D, Lacaille D, LaValley MP, Aletaha D, et al
     Response to: Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment' by Felson et al.
     Ann Rheum Dis. 2022 Feb 17. pii: annrheumdis-2021-221941.
     PubMed    
     
     
     
121. FERREIRA RJO, Welsing PMJ, Jacobs JW, Gossec L, et al
     Correspondence on 'Re-examining remission definitions in rheumatoid arthritis: considering the 28-joint Disease Activity Score, C reactive protein level and patient global assessment' by Felson et al.
     Ann Rheum Dis. 2022 Feb 17. pii: annrheumdis-2021-221917.
     PubMed    
     
     
     
122. JIN S, Jiang N, Huo Y, Duan X, et al
     Management of rheumatoid arthritis in China: a study of the implementation of 2019 EULAR recommendations.
     Ann Rheum Dis. 2022 Feb 15. pii: annrheumdis-2021-221841.
     PubMed    
     
     
     
123. TEDESCHI SK, Stratton J, Ellrodt JE, Whelan MG, et al
     Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine.
     Ann Rheum Dis. 2022 Feb 15. pii: annrheumdis-2022-222232.
     PubMed    
     
     
     
124. MEDEIROS-RIBEIRO AC, Bonfiglioli KR, Domiciano DS, Shimabuco AY, et al
     Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis.
     Ann Rheum Dis. 2022 Feb 8. pii: annrheumdis-2021-221735.
     PubMed     Abstract available
     
     
     
125. SYMONS RA, Colella F, Collins FL, Rafipay AJ, et al
     Targeting the IL-6-Yap-Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis.
     Ann Rheum Dis. 2022;81:214-224.
     PubMed     Abstract available
     
     
     
126. VAN DER HELM-VAN MIL A, Landewe RB
     Response to: 'The cost of arthralgia 'pretreatment' to prevent rheumatoid arthritis' by Rothschild.
     Ann Rheum Dis. 2022;81:e19.
     PubMed    
     
     
     
127. ROTHSCHILD BM
     The cost of arthralgia 'pretreatment' to prevent rheumatoid arthritis.
     Ann Rheum Dis. 2022;81:e18.
     PubMed    
     
     
     January 2022
128. KHOSROW-KHAVAR F, Kim SC, Lee H, Lee SB, et al
     Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.
     Ann Rheum Dis. 2022 Jan 13. pii: annrheumdis-2021-221915.
     PubMed     Abstract available
     
     
     
129. GE C, Weisse S, Xu B, Dobritzsch D, et al
     Key interactions in the trimolecular complex consisting of the rheumatoid arthritis-associated DRB1*04:01 molecule, the major glycosylated collagen II peptide and the T-cell receptor.
     Ann Rheum Dis. 2022 Jan 13. pii: annrheumdis-2021-220500.
     PubMed     Abstract available
     
     
     
130. 
     Correction: Parsing multiomics landscape of activated synovial fibroblasts highlights drug targets linked to genetic risk of rheumatoid arthritis.
     Ann Rheum Dis. 2022;81:e17.
     PubMed    
     
     
     
131. LEE YH
     Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study.
     Ann Rheum Dis. 2022;81:e3.
     PubMed    
     
     
     
132. INAMO J
     Response to: 'Causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation study' by Lee.
     Ann Rheum Dis. 2022;81:e4.
     PubMed    
     
     
     
133. KISSEL T, van Wesemael TJ, Lundquist A, Kokkonen H, et al
     Genetic predisposition (HLA-SE) is associated with ACPA-IgG variable domain glycosylation in the predisease phase of RA.
     Ann Rheum Dis. 2022;81:141-143.
     PubMed    
     
     
     December 2021
134. BUGATTI S, De Stefano L, Balduzzi S, Greco MI, et al
     Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis.
     Ann Rheum Dis. 2021;80:1635-1638.
     PubMed    
     
     
     
135. ROSENZWAJG M, Lorenzon R, Klatzmann D
     Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer et al.
     Ann Rheum Dis. 2021;80:e197.
     PubMed    
     
     
     
136. MEYER A, Wittekind PS, Kotschenreuther K, Schiller J, et al
     Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.
     Ann Rheum Dis. 2021;80:e196.
     PubMed    
     
     
     
137. PEREZ-GARCIA LF, Roder E, Goekoop RJ, Hazes JMW, et al
     Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility).
     Ann Rheum Dis. 2021;80:1545-1552.
     PubMed     Abstract available
     
     
     
138. GRAALMANN T, Borst K, Manchanda H, Vaas L, et al
     B cell depletion impairs vaccination-induced CD8(+) T cell responses in a type I interferon-dependent manner.
     Ann Rheum Dis. 2021;80:1537-1544.
     PubMed     Abstract available
     
     
     November 2021
139. SIMADER E, Tobudic S, Mandl P, Haslacher H, et al
     Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis.
     Ann Rheum Dis. 2021 Nov 29. pii: annrheumdis-2021-221347.
     PubMed     Abstract available
     
     
     
140. BALSA A, Garcia de Yebenes MJ, Carmona L
     Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study.
     Ann Rheum Dis. 2021 Nov 29. pii: annrheumdis-2021-221163.
     PubMed     Abstract available
     
     
     
141. FELSON D, Lacaille D, LaValley MP, Aletaha D, et al
     Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment.
     Ann Rheum Dis. 2021 Nov 16. pii: annrheumdis-2021-221653.
     PubMed    
     
     
     
142. SIDDLE HJ, Chapman LS, Mankia K, Zabalan C, et al
     Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies.
     Ann Rheum Dis. 2021 Nov 8. pii: annrheumdis-2021-221160.
     PubMed     Abstract available
     
     
     
143. WINTHROP KL, Tanaka Y, Takeuchi T, Kivitz A, et al
     Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
     Ann Rheum Dis. 2021 Nov 5. pii: annrheumdis-2021-221051.
     PubMed     Abstract available
     
     
     
144. TANAKA Y, Oba K, Takeuchi T
     Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al' by Berkhout et al.
     Ann Rheum Dis. 2021;80:e173.
     PubMed    
     
     
     
145. BERKHOUT LC, l'Ami MJ, Wolbink GJ, Rispens T, et al
     Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka et al.
     Ann Rheum Dis. 2021;80:e172.
     PubMed    
     
     
     
146. CHEN MH, Lee IC, Chen MH, Hou MC, et al
     Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease.
     Ann Rheum Dis. 2021;80:1393-1399.
     PubMed     Abstract available
     
     
     
147. NABI H, Georgiadis S, Loft AG, Hendricks O, et al
     Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.
     Ann Rheum Dis. 2021;80:1400-1409.
     PubMed     Abstract available
     
     
     October 2021
148. TAYLOR PC, Takeuchi T, Burmester GR, Durez P, et al
     Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.
     Ann Rheum Dis. 2021 Oct 27. pii: annrheumdis-2021-221276.
     PubMed     Abstract available
     
     
     
149. LI X, Tong X, Yeung WWY, Kuan P, et al
     Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong.
     Ann Rheum Dis. 2021 Oct 22. pii: annrheumdis-2021-221571.
     PubMed     Abstract available
     
     
     
150. CHRISTENSEN IE, Lillegraven S, Mielnik P, Bakland G, et al
     Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.
     Ann Rheum Dis. 2021 Oct 8. pii: annrheumdis-2021-221007.
     PubMed     Abstract available
     
     
     
151. IBANEZ-COSTA A, Perez-Sanchez C, Patino-Trives AM, Luque-Tevar M, et al
     Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy.
     Ann Rheum Dis. 2021 Oct 8. pii: annrheumdis-2021-220308.
     PubMed     Abstract available
     
     
     
152. WINTHROP KL, Nash P, Yamaoka K, Mysler E, et al
     Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.
     Ann Rheum Dis. 2021 Oct 6. pii: annrheumdis-2021-220822.
     PubMed     Abstract available
     
     
     
153. CAPELUSNIK D, Aletaha D
     Baseline predictors of different types of treatment success in rheumatoid arthritis.
     Ann Rheum Dis. 2021 Oct 4. pii: annrheumdis-2021-220853.
     PubMed     Abstract available
     
     
     
154. FLOUDAS A, Neto N, Orr C, Canavan M, et al
     Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis.
     Ann Rheum Dis. 2021 Oct 1. pii: annrheumdis-2021-220458.
     PubMed     Abstract available
     
     
     
155. MEEHAN GR, Thomas R, Al Khabouri S, Wehr P, et al
     Preclinical models of arthritis for studying immunotherapy and immune tolerance.
     Ann Rheum Dis. 2021;80:1268-1277.
     PubMed     Abstract available
     
     
     
156. NIKIPHOROU E, Santos EJF, Marques A, Bohm P, et al
     2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis.
     Ann Rheum Dis. 2021;80:1278-1285.
     PubMed     Abstract available
     
     
     September 2021
157. YOSHII I, Sawada N, Chijiwa T, Kokei S, et al
     Impact of sustaining SDAI remission for preventing incident of bone fragility fracture in patient with rheumatoid arthritis.
     Ann Rheum Dis. 2021 Sep 11. pii: annrheumdis-2021-221093.
     PubMed    
     
     
     
158. MINOIA F, Ravelli A
     Response to 'Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease' by Wang et al.
     Ann Rheum Dis. 2021;80:e146.
     PubMed    
     
     
     
159. WANG R, Li T, Ye S, Tan W, et al
     Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease.
     Ann Rheum Dis. 2021;80:e145.
     PubMed    
     
     
     
160. OZEN G, Michaud K
     Response to: 'Medications associated with fracture risk in patients with rheumatoid arthritis' by Chen et al.
     Ann Rheum Dis. 2021;80:e141.
     PubMed    
     
     
     
161. JONSSON R
     Henrik Sjogren (1899-1986): the syndrome and his legacy.
     Ann Rheum Dis. 2021;80:1108-1109.
     PubMed    
     
     
     
162. MAASSEN JM, Dos Santos Sobrin R, Bergstra SA, Goekoop R, et al
     Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies.
     Ann Rheum Dis. 2021;80:1124-1129.
     PubMed     Abstract available
     
     
     
163. LIOU YS, Lin TK, Chen HY, Jong GP, et al
     Medications associated with fracture risk in patients with rheumatoid arthritis.
     Ann Rheum Dis. 2021;80:e140.
     PubMed    
     
     
     August 2021
164. HECKERT SL, Bergstra SA, Matthijssen XME, Goekoop-Ruiterman YPM, et al
     Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course.
     Ann Rheum Dis. 2021 Aug 30. pii: annrheumdis-2021-220882.
     PubMed     Abstract available
     
     
     
165. WANG Y, Xie X, Zhang C, Su M, et al
     Rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren's syndrome shared megakaryocyte expansion in peripheral blood.
     Ann Rheum Dis. 2021 Aug 30. pii: annrheumdis-2021-220066.
     PubMed     Abstract available
     
     
     
166. WALLACE ZS, Sparks JA, Robinson PC, Machado PM, et al
     Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.
     Ann Rheum Dis. 2021 Aug 23. pii: annrheumdis-2021-220960.
     PubMed    
     
     
     
167. GREMESE E, Ferraccioli G
     Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry" by Sparks et al.
     Ann Rheum Dis. 2021 Aug 23. pii: annrheumdis-2021-220932.
     PubMed    
     
     
     
168. NAGY G, Roodenrijs NMT, Welsing PMJ, Kedves M, et al
     EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.
     Ann Rheum Dis. 2021 Aug 18. pii: annrheumdis-2021-220973.
     PubMed     Abstract available
     
     
     
169. VAN VOLLENHOVEN RF, Tas SW, Nurmohamed MT
     Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry" by Sparks et al.
     Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-221146.
     PubMed    
     
     
     
170. HOLTEN K, Paulshus Sundlisater N, Lillegraven S, Sexton J, et al
     Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment.
     Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-220750.
     PubMed     Abstract available
     
     
     
171. SPARKS JA, Wallace ZS, Seet AM, Robinson PC, et al
     Response to: Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis" by Sparks et al.
     Ann Rheum Dis. 2021 Aug 13. pii: annrheumdis-2021-221157.
     PubMed    
     
     
     
172. PLATZER A, Alasti F, Smolen JS, Aletaha D, et al
     Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables.
     Ann Rheum Dis. 2021 Aug 10. pii: annrheumdis-2021-220331.
     PubMed     Abstract available
     
     
     
173. MANKIA K, Siddle HJ, Kerschbaumer A, Alpizar Rodriguez D, et al
     EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.
     Ann Rheum Dis. 2021 Aug 6. pii: annrheumdis-2021-220884.
     PubMed     Abstract available
     
     
     
174. NASONOV E, Fatenejad S, Feist E, Ivanova M, et al
     Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.
     Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-219876.
     PubMed     Abstract available
     
     
     
175. SPARKS JA
     Towards clinical significance of the MUC5B promoter variant and risk of rheumatoid arthritis-associated interstitial lung disease.
     Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-220856.
     PubMed    
     
     
     
176. PALOMAKI A, Palotie A, Koskela J, Eklund KK, et al
     Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers.
     Ann Rheum Dis. 2021 Aug 3. pii: annrheumdis-2021-220698.
     PubMed     Abstract available
     
     
     
177. VALLEJO-YAGUE E, Keystone EC, Kandhasamy S, Micheroli R, et al
     Primary and secondary non-response: in need of operational definitions in observational studies.
     Ann Rheum Dis. 2021;80:961-964.
     PubMed    
     
     
     
178. NAKAMURA H, Tanaka T, Pranzatelli T, Ji Y, et al
     Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjogren's syndrome-like phenotype in mice.
     Ann Rheum Dis. 2021;80:1031-1039.
     PubMed     Abstract available
     
     
     
179. WANG H, Stewart S, Darlow B, Horgan B, et al
     Patient research partner involvement in rheumatology clinical trials: analysis of journal articles 2016-2020.
     Ann Rheum Dis. 2021;80:1095-1096.
     PubMed    
     
     
     
180. BOWER H, Frisell T, Di Giuseppe D, Delcoigne B, et al
     Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study.
     Ann Rheum Dis. 2021;80:1086-1093.
     PubMed     Abstract available
     
     
     
181. MATTHIJSSEN XME, Wouters F, Sidhu N, Niemantsverdriet E, et al
     Tenosynovitis has a high sensitivity for early ACPA-positive and ACPA-negative RA: a large cross-sectional MRI study.
     Ann Rheum Dis. 2021;80:974-980.
     PubMed     Abstract available
     
     
     
182. ASSAN F, Seror R, Mariette X, Nocturne G, et al
     New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS.
     Ann Rheum Dis. 2021;80:e122.
     PubMed    
     
     
     July 2021
183. REDEKER I, Albrecht K, Kekow J, Burmester GR, et al
     Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register.
     Ann Rheum Dis. 2021 Jul 28. pii: annrheumdis-2021-220651.
     PubMed     Abstract available
     
     
     
184. WOUTERS F, Maurits MP, van Boheemen L, Verstappen M, et al
     Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis.
     Ann Rheum Dis. 2021 Jul 20. pii: annrheumdis-2021-220546.
     PubMed     Abstract available
     
     
     
185. 
     Retraction: Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis.
     Ann Rheum Dis. 2021 Jul 6. pii: annrheumdis-2017-211351.
     PubMed    
     
     
     
186. DUMOULIN QA, Matthijssen XME, Wouters F, Krijbolder DI, et al
     Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'.
     Ann Rheum Dis. 2021 Jul 5. pii: annrheumdis-2021-220511.
     PubMed    
     
     
     
187. GESSL I, Aletaha D, Mandl P
     Response to: 'Correspondence on 'Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis'' by Dumoulin et al.
     Ann Rheum Dis. 2021 Jul 5. pii: annrheumdis-2021-220922.
     PubMed    
     
     
     
188. OCON AJ, Reed G, Pappas DA, Curtis JR, et al
     Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.
     Ann Rheum Dis. 2021 Jul 2. pii: annrheumdis-2021-220577.
     PubMed     Abstract available
     
     
     
189. WONG AY, MacKenna B, Morton CE, Schultze A, et al
     Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.
     Ann Rheum Dis. 2021;80:943-951.
     PubMed     Abstract available
     
     
     
190. JOUSSE-JOULIN S, D'Agostino MA, Hocevar A, Naredo E, et al
     Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's sy
     Ann Rheum Dis. 2021;80:e112.
     PubMed    
     
     
     
191. LAI SW, Kuo YH, Liao KF
     Chronic hydroxychloroquine exposure and the risk of Alzheimer's disease.
     Ann Rheum Dis. 2021;80:e105.
     PubMed    
     
     
     
192. COIFFIER G, Martel A, Albert JD, Lescoat A, et al
     Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?
     Ann Rheum Dis. 2021;80:e111.
     PubMed    
     
     
     
193. TRAVES PG, Murray B, Campigotto F, Galien R, et al
     JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
     Ann Rheum Dis. 2021;80:865-875.
     PubMed     Abstract available
     
     
     June 2021
194. JAIN S, Dhir V
     Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'.
     Ann Rheum Dis. 2021 Jun 30. pii: annrheumdis-2021-220816.
     PubMed    
     
     
     
195. STOUTEN V, Westhovens R, Pazmino S, De Cock D, et al
     Response to: 'Correspondence on 'Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial'' by Jain and Dhir et al.
     Ann Rheum Dis. 2021 Jun 30. pii: annrheumdis-2021-220857.
     PubMed    
     
     
     
196. ALBACH FN, Burmester GR, Biesen R
     Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
     Ann Rheum Dis. 2021 Jun 24. pii: annrheumdis-2021-220834.
     PubMed    
     
     
     
197. SHIPA MRA, Amarnani R, Yeoh SA, Mainuddin MD, et al
     Early reduction in circulating monocyte count predicts maintenance of remission in patients with rheumatoid arthritis treated with anti-TNF therapy.
     Ann Rheum Dis. 2021 Jun 23. pii: annrheumdis-2021-220642.
     PubMed    
     
     
     
198. JAIN S, Dhir V, Aggarwal A, Gupta R, et al
     Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial.
     Ann Rheum Dis. 2021 Jun 10. pii: annrheumdis-2021-220512.
     PubMed     Abstract available
     
     
     
199. PAULSHUS SUNDLISATER N, Aga AB, Olsen IC, Hammer HB, et al
     Joint tenderness and ultrasound inflammation in DMARD-naive patients with early rheumatoid arthritis.
     Ann Rheum Dis. 2021 Jun 3. pii: annrheumdis-2021-220265.
     PubMed    
     
     
     
200. CROW MK
     Charles L Christian: model physician scientist and mentor.
     Ann Rheum Dis. 2021;80:685-688.
     PubMed    
     
     
     
201. ANSALONE C, Cole J, Chilaka S, Sunzini F, et al
     TNF is a homoeostatic regulator of distinct epigenetically primed human osteoclast precursors.
     Ann Rheum Dis. 2021;80:748-757.
     PubMed     Abstract available
     
     
     
202. HAYER S, Vervoordeldonk MJ, Denis MC, Armaka M, et al
     'SMASH' recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal models.
     Ann Rheum Dis. 2021;80:714-726.
     PubMed     Abstract available
     
     
     May 2021
203. SPARKS JA, Wallace ZS, Seet AM, Gianfrancesco MA, et al
     Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
     Ann Rheum Dis. 2021 May 28. pii: annrheumdis-2021-220418.
     PubMed     Abstract available
     
     
     
204. JOHNSON TM, Sayles HR, Baker JF, George MD, et al
     Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.
     Ann Rheum Dis. 2021 May 28. pii: annrheumdis-2021-220125.
     PubMed     Abstract available
     
     
     
205. D'ONOFRIO B, De Stefano L, Palermo BL, Xoxi B, et al
     Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19.
     Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220219.
     PubMed    
     
     
     
206. LIN TK, Pan LF, Jong GP
     Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
     Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220453.
     PubMed    
     
     
     
207. GONG Z, Zhang F
     Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study'.
     Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220494.
     PubMed    
     
     
     
208. ABTAHI S, Driessen JHM, Burden AM, Souverein PC, et al
     Response to: 'Correspondence on 'Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study' by Gong and Zhang and Lin et al.
     Ann Rheum Dis. 2021 May 26. pii: annrheumdis-2021-220477.
     PubMed    
     
     
     
209. TAKANASHI S, Kaneko Y, Takeuchi T
     Elderly patients with comorbidities in the definition of difficult-to-treat rheumatoid arthritis.
     Ann Rheum Dis. 2021 May 7. pii: annrheumdis-2021-220315.
     PubMed    
     
     
     
210. 
     Correction: Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
     Ann Rheum Dis. 2021;80:e83.
     PubMed    
     
     
     
211. ROGIER C, van Dijk BT, Brouwer E, de Jong PHP, et al
     Realising early recognition of arthritis in times of increased telemedicine: the value of patient-reported swollen joints.
     Ann Rheum Dis. 2021;80:668-669.
     PubMed    
     
     
     
212. SCHULZE-KOOPS H, Krueger K, Vallbracht I, Hasseli R, et al
     Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab.
     Ann Rheum Dis. 2021;80:e67.
     PubMed    
     
     
     
213. ROMAO VC, Cruz-Machado AR, Fonseca JE
     Response to: 'The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients' by Favalli et al.
     Ann Rheum Dis. 2021;80:e76.
     PubMed    
     
     
     
214. ZHAO J, Pang R, Wu J, Guo Y, et al
     Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences.
     Ann Rheum Dis. 2021;80:e63.
     PubMed    
     
     
     
215. MOENTADJ R, Wang Y, Bowerman K, Rehaume L, et al
     Streptococcus species enriched in the oral cavity of patients with RA are a source of peptidoglycan-polysaccharide polymers that can induce arthritis in mice.
     Ann Rheum Dis. 2021;80:573-581.
     PubMed     Abstract available
     
     
     
216. KAJIO N, Takeshita M, Suzuki K, Kaneda Y, et al
     Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling.
     Ann Rheum Dis. 2021;80:651-659.
     PubMed     Abstract available
     
     
     April 2021
217. ROONGTA R, Chattopadhyay A, Ghosh A
     Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'
     Ann Rheum Dis. 2021 Apr 27. pii: annrheumdis-2021-220479.
     PubMed    
     
     
     
218. DERKSEN VFAM, van der Woude D
     Response to: 'Correspondence on 'Onset of rheumatoid arthritis after COVID-19: coincidence or connected?'' by Roongta et al.
     Ann Rheum Dis. 2021 Apr 27. pii: annrheumdis-2021-220516.
     PubMed    
     
     
     
219. INGEGNOLI F, Cincinelli G, Luppino AF, Favalli EG, et al
     Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy.
     Ann Rheum Dis. 2021 Apr 13. pii: annrheumdis-2021-220142.
     PubMed    
     
     
     
220. MIYAZAKI Y, Nakano K, Nakayamada S, Kubo S, et al
     Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
     Ann Rheum Dis. 2021 Apr 7. pii: annrheumdis-2020-219699.
     PubMed     Abstract available
     
     
     
221. XIE W, Huang H, Li G, Hao Y, et al
     Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020.
     Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2021-220112.
     PubMed     Abstract available
     
     
     
222. STOUTEN V, Westhovens R, Pazmino S, De Cock D, et al
     Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.
     Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2020-219825.
     PubMed     Abstract available
     
     
     
223. SO H, Cheng IT, Lau SL, Chow E, et al
     Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial.
     Ann Rheum Dis. 2021 Apr 2. pii: annrheumdis-2021-219846.
     PubMed     Abstract available
     
     
     
224. GUPTA L, Misra DP, Agarwal V, Balan S, et al
     Response to: 'Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort' by Costa et al.
     Ann Rheum Dis. 2021;80:e47.
     PubMed    
     
     
     March 2021
225. FELTEN R, Devauchelle-Pensec V, Seror R, Duffau P, et al
     Interleukin 6 receptor inhibition in primary Sjogren syndrome: a multicentre double-blind randomised placebo-controlled trial.
     Ann Rheum Dis. 2021;80:329-338.
     PubMed     Abstract available
     
     
     
226. BAER AN, Gottenberg JE, St Clair EW, Sumida T, et al
     Efficacy and safety of abatacept in active primary Sjogren's syndrome: results of a phase III, randomised, placebo-controlled trial.
     Ann Rheum Dis. 2021;80:339-348.
     PubMed     Abstract available
     
     
     
227. AKIYAMA S, Hamdeh S, Micic D, Sakuraba A, et al
     Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.
     Ann Rheum Dis. 2021;80:384-391.
     PubMed     Abstract available
     
     
     
228. LIEW JW, Graef ER
     Rheumatic disease and COVID-19.
     Ann Rheum Dis. 2021;80:e43.
     PubMed    
     
     
     
229. MONTI S, Montecucco C
     Candidate rheumatologic treatments for COVID-19. Response to: 'COVID-19 infection in a patient with FMF: does colchicine have a protective effect?' by Kobak.
     Ann Rheum Dis. 2021;80:e40.
     PubMed    
     
     
     
230. WALLACE B, Washer L, Marder W, Kahlenberg JM, et al
     Patients with lupus with COVID-19: University of Michigan experience.
     Ann Rheum Dis. 2021;80:e35.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Rheumatoid Arthritis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: